Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Nat Rev Immunol
Authors
Keywords
Abstract

Cancer vaccines, which are designed to amplify tumour-specific T cell responses through active immunization, have long been envisioned as a key tool of effective cancer immunotherapy. Despite a clear rationale for such vaccines, extensive past efforts were unsuccessful in mediating clinically relevant antitumour activity in humans. Recently, however, next-generation sequencing and novel bioinformatics tools have enabled the systematic discovery of tumour neoantigens, which are highly desirable immunogens because they arise from somatic mutations of the tumour and are therefore tumour specific. As a result of the diversity of tumour neoepitopes between individuals, the development of personalized cancer vaccines is warranted. Here, we review the emerging field of personalized cancer vaccination and discuss recent developments and future directions for this promising treatment strategy.

Year of Publication
2018
Journal
Nat Rev Immunol
Volume
18
Issue
3
Pages
168-182
Date Published
2018 03
ISSN
1474-1741
DOI
10.1038/nri.2017.131
PubMed ID
29226910
PubMed Central ID
PMC6508552
Links
Grant list
R01 CA155010 / CA / NCI NIH HHS / United States
R01 HL103532 / HL / NHLBI NIH HHS / United States
T32 CA207021 / CA / NCI NIH HHS / United States